Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asad Bashey

Showing results (21-30 of 128) with videos related to

Pageof 13
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 21, 2016
Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single CenterMelhem Solh, Xu Zhang, Katelin Connor, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2018
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid LeukemiaBruno C Medeiros, Tiffany N Tanaka, Larisa Balaian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 8, 2019
Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?Eva Karam, Justin Laporte, Scott R Solomon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2016
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute LeukemiaScott R Solomon, Connie A Sizemore, Xu Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 24, 2015
Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling DonorsScott R Solomon, Connie A Sizemore, Melissa Sanacore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 7, 2012
Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trialScott R Solomon, Connie A Sizemore, Melissa Sanacore, et al.
Advances in Hematology|April 16, 2021
A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic MalignanciesMelhem M Solh, Gabriel Hinojosa, Justin Laporte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantationAsad Bashey, Xu Zhang, Connie A Sizemore, et al.
Blood Advances|August 11, 2020
Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplantScott R Solomon, Melhem Solh, Xu Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2016
T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor TransplantationJessica Gorgeis, Xu Zhang, Katelin Connor, et al.
Pageof 13

Showing results (21-30 of 128) with videos related to

Sort By:
Pageof 13
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 21, 2016
Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single CenterMelhem Solh, Xu Zhang, Katelin Connor, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2018
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid LeukemiaBruno C Medeiros, Tiffany N Tanaka, Larisa Balaian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 8, 2019
Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?Eva Karam, Justin Laporte, Scott R Solomon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2016
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute LeukemiaScott R Solomon, Connie A Sizemore, Xu Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 24, 2015
Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling DonorsScott R Solomon, Connie A Sizemore, Melissa Sanacore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 7, 2012
Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trialScott R Solomon, Connie A Sizemore, Melissa Sanacore, et al.
Advances in Hematology|April 16, 2021
A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic MalignanciesMelhem M Solh, Gabriel Hinojosa, Justin Laporte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantationAsad Bashey, Xu Zhang, Connie A Sizemore, et al.
Blood Advances|August 11, 2020
Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplantScott R Solomon, Melhem Solh, Xu Zhang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2016
T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor TransplantationJessica Gorgeis, Xu Zhang, Katelin Connor, et al.
Pageof 13